U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

https://www.globenewswire.com/news-release/2023/12/23/2800891/0/en/U-S-Food-and-Drug-Administration-issues-Complete-Response-Letter-for-dasiglucagon-in-congenital-hyperinsulinism-for-up-to-three-weeks-of-dosing-due-to-inspection-findings-at-third-.html

company announcement